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ABSTRACT
The human androgen receptor (AR) gene contains a variable num-
ber of CAG repeats within exon 1. Shorter AR alleles, by increasing
transactivation, may result in augmented AR-mediated sensitivity of
the hair follicle. We have evaluated whether the number of CAG
repeats, or if skewed inactivation of X-chromosome, favoring the pres-
ence of shorter AR alleles, influence hirsutism in women with and
without hyperandrogenemia. Twenty-eight women with idiopathic
hirsutism (normal serum androgens), 34 women with hyperandro-
genic hirsutism (increased serum androgens), and 15 healthy control
women were analyzed by evaluating the number of CAG repeats in
genomic DNA, as well as the methylation pattern (after DNA diges-
tion with HpaII), which allows identification of which allele is
inactive. Despite marked differences among the groups in serum
androgens, which were markedly increased in women with hyperan-
drogenic hirsutism as compared with women with idiopathic hirsut-
ism and to controls, there were no significant differences among the
groups in the number of CAG repeats. Moreover, skewed X-chromo-
some inactivation was found in 10 subjects (3 with idiopathic hirsut-
ism, 5 with hyperandrogenic hirsutism, and 2 controls; P 5 0.746) of
the 67 women (14.9%) who were heterozygous for the AR gene. In
several of these subjects, it was the shorter allele that was prefer-
entially inactivated.
In conclusion, neither the CAG repeat polymorphism in the AR
gene, nor skewed X-chromosome inactivation, seem to play a signif-
icant role in the pathogenesis of hirsutism. (J Clin Endocrinol Metab
85: 1735–1740, 2000)
HIRSUTISM is considered to be a consequence of in-creased androgen action at the pilosebaceous unit.
Most hirsute patients have abnormalities in the adrenal
and/or ovarian steroidogenesis, resulting in serum andro-
gen excess, which is responsible for their hirsutism (1, 2).
However, a significant proportion of hirsute patients have
normal serum androgen concentrations, a condition usually
termed as idiopathic hirsutism (3). The pathogenesis of hir-
sutism in these women is not known but might be related to
a putative increase in the sensitivity of the hair follicle to
androgens, resulting from abnormalities in the androgen
signal transduction system in the skin.
The androgen receptor (AR) is a member of the steroid
receptor superfamily and is encoded in the X-chromosome
(4, 5). The AR gene contains, within exon 1, a polymorphic
CAG repeat sequence, which encodes for a polyglutamine
chain of variable length in the aminoterminal transactivation
domain of the protein (6). The expansion of the CAG repeats
length results in a linear decrease in the transactivation func-
tion of the AR (6), and inverse relationships have been de-
scribed between the number of CAG triplets in the AR gene
with the risk for prostate cancer and its severity (7, 8), and
with the hirsutism scores in Hispanic females (9). Moreover,
shorter AR gene alleles have been described in association
with androgenic disorders of the skin in men and women,
including acne, androgenetic alopecia, and hirsutism, as
compared with healthy controls (10).
Recently, skewed X-chromosome inactivation has been
proposed by Vottero et al. (11) to play a role in the hypo-
thetical hypersensitivity of the AR to androgens in women
with idiopathic hirsutism. Methylation of HpaII and HhaI
sites near the CAG triplets in exon 1 of the AR gene correlates
with X-chromosome inactivation (12). From the study of the
AR gene methylation pattern in 16 nonhyperandrogenic hir-
sute patients and 10 healthy control women, Vottero et al. (11)
concluded that skewed inactivation of the longer of the two
AR alleles, allowing for the shorter (and presumably more
functional) AR allele to be expressed on the active X-chro-
mosome, might explain the peripheral hypersensitivity to
androgens present in these women.
As will be seen, after studying a large series of women
diagnosed with idiopathic (nonhyperandrogenic) hirsutism
or with hyperandrogenic hirsutism, as compared with
healthy women, we have found that the polymorphic CAG
repeat in exon 1 of the AR gene and skewed X-chromosome
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inactivation seem to play no significant role in the patho-
genesis of hirsutism.
Subjects and Methods
Subjects
Sixty-two unselected hirsute women [age, 23.1 6 (sd) 6.9 yr; body
mass index (BMI), 25.36 6 (sd) 6.1 kg/m2] were recruited for the study.
Most of the patients did not have a family history of hyperandrogenic
disorders. Hirsutism was defined by the presence of terminal hair in an
androgen-dependent pattern, with a Ferriman-Gallwey score of 8 or
more (13). None of the patients had hypertension, features of Cushing’s
disease, or drug-induced hirsutism. Hyperprolactinemia, thyroid dis-
ease, congenital adrenal hyperplasia, and acromegaly were ruled out by
appropriate testing.
The reference values for the analytical procedures were obtained from
a control group of 15 normal menstruating women [age, 29.5 6 (sd) 8.1
yr; matched for BMI, 23.7 6 (sd) 4.2 kg/m2] who did not have signs and
symptoms of hyperandrogenism or a family history of endocrine dis-
eases. None of the patients or controls had taken hormonal medications,
including contraceptive pills, for the last 6 months. All the patients and
controls were Caucasians, living in Madrid, Spain. This study was ap-
proved by the hospital ethics committee, and informed consent was
obtained from each patient and control.
Functional evaluation
Studies were performed between days 5 and 10 of the menstrual cycle,
or during amenorrhea, after excluding pregnancy by appropriate test-
ing. The patients reported to the Endocrine-Metabolic testing room
between 0800 h and 0900 h after a 12-h overnight fast. An indwelling iv
line was placed in a forearm vein, and, after 15–30 min, basal blood
samples were obtained for measurement of total testosterone (T), de-
hydroepiandrosterone-sulfate (DHEAS), LH, FSH, estradiol (E2), sex
hormone-binding globulin (SHBG), cortisol (F), 11-deoxycortisol (S),
progesterone (P4), 17-hydroxyprogesterone (17-OHP), and 4-andro-
stenedione (A). All blood samples were immediately centrifuged, and
serum was separated and frozen at 220 C until assayed.
Women were considered to have idiopathic (nonhyperandrogenic)
hirsutism (n 5 28) when the basal serum concentrations of T, DHEAS,
and A were within the normal range derived from the control group of
15 healthy women. The upper limits of normality for serum androgens
were 2.46 nmol/L, 10.8 mmol/L, and 14.0 nmol/L, for T, DHEAS, and
A, respectively. Women with increased concentrations of any of these
androgens were considered to have hyperandrogenic hirsutism (n 5 34).
Part of the hormonal data from 40 patients and 13 control women
have been included in previous reports (1, 2, 14–17), regarding aspects
of the pathophysiology of functional hyperandrogenism different from
those studied here.
Hormone assays
Serum T, LH, FSH, E2, SHBG, F, S, 17-OHP, P4, DHEAS, and A were
measured as published previously (1, 2, 14). The free androgen index
was calculated using the formula [T (nmol/L) 3 100]/SHBG (nmol/L)].
Determination of the number of CAG repeats in exon 1 of
the AR
In addition to serum samples, whole blood samples were collected
from all women. Genomic DNA was extracted from peripheral leuko-
cytes following the manufacturer’s instructions (Wizard Genomic DNA
Purification Kit, Promega Corp., Madison, WI; and Nucleon BAC C3,
Amersham-Life Science, Buckinghamshire, UK). DNA from all subjects
in the study was used to amplify the polymorphic (CAG)n repeat of the
human AR. PCR mixtures contained 10 mm Tris (pH 8.3), 50 mm KCl,
1.5 mm MgCl2, 200 mm dNTP, 20 pmol of each primer, and 1 U Taq
polymerase (PE Applied Biosystems, Foster City, CA). The primers used
for the amplification were 59-TCCAGAATCTGTTCCAGAGCGTGC-39
labeled with TET fluorescent dye and 59-GCTGTGAAGGTTGCTGTTC-
CTCAT-39 (12). Amplifications were performed by using an automated
thermocycler (GeneAmp PCR System 2400; PE Applied Biosystems)
applying the following conditions: an initial denaturating step at 94 C
for 5 min, 32 cycles at 94 C for 1 min, at 58 C for 1 min, and at 72 C for
1 min, and a final extension at 72 C for 7 min. PCR products were
individually diluted, and 1–2 mL were mixed with deionized formamide
and a fluorescent molecular weight marker (PE Applied Biosystems).
After denaturation for 5 min at 96 C, each sample was analyzed by
capillary electrophoresis on an ABI 310A automated sequencer, and the
PCR products were analyzed by GeneScan software (PE Applied Bio-
systems). The number of CAG repeats was calculated from the size of
the PCR products, in relation to a series of standards obtained by direct
sequencing of PCR products from five homozygous individuals.
X-chromosome inactivation analysis
The X-chromosome inactivation assay based on the AR gene meth-
ylation pattern using lymphocyte DNA has been described previously
(12). HpaII digests only the unmethylated DNA. Methylation of HpaII
site close to the (CAG)n repeat correlates with X inactivation. The site
is methylated on the inactive X-chromosome and, therefore, resists
cleavage by HpaII, and a PCR product is obtained from the inactive
X-chromosome only.
We have used the technique modified by Pegoraro et al. (18) for use
on an ABI 310 automated sequencer. In brief, for each DNA sample two
reactions were prepared; in one, 1 mg DNA sample was digested with
20 U HpaII at 37 C overnight. A second aliquot with another microgram
of the same DNA containing the enzyme digestion buffer but no enzyme
was incubated in parallel. Reactions were stopped by incubation at 96
C for 5 min. Both digested and undigested DNA (200 ng) were used for
PCR amplifications. Primers and conditions were as above. All samples
were amplified and analyzed, at least in duplicate, and, for each indi-
vidual, the mean of these measurements was used for statistical analysis.
To quantitate the relative inactivation of AR alleles, the area of the
peaks of both alleles using undigested and digested DNA were obtained
using the GeneScan software. For each patient the ratio between the
areas of the two alleles using undigested PCR product was calculated
and used as correction factor. This correction factor was applied to
compensate for unequal amplification of alleles, using digested PCR
product. The degree of X-chromosome inactivation was then calculated
by normalizing the sum of both alleles to 100%, and each allele was then
expressed as percentage. For example, if all the cells have the same
inactive X-chromosome, only one PCR product will be obtained and the
result would be 100%, whereas if X-chromosome inactivation is com-
pletely random, the result would be 50%, indicating an equal number
of cells having each of the two alleles. As discussed previously by
Naumova et al. (19), an 80% or higher percentage for one allele is
considered as indicative of skewed X-chromosome inactivation.
Power calculations, sample size, and statistical analysis
The power of the study to evaluate differences in the mean number
of CAG repeats in the AR gene among the 28 women with idiopathic
hirsutism, compared with the 34 women with hyperandrogenic hirsut-
ism, was found to be 0.82 for the detection of differences in the means
of both groups of two or more CAG repeats (a 5 0.05, one-sided test,
normal distribution, variance derived from the study population) (20).
Vottero et al. (11) have reported that 69% of the patients with non-
hyperadrogenic hirsutism show skewed X-chromosome inactivation.
Assuming that, for skewed X-chromosome inactivation to play a sig-
nificant role in the pathogenesis of idiopathic hirsutism, it must be
present in at least 50% of these women and that skewed X-chromosome
inactivation should be found in women with hyperandrogenic hirsutism
in the same proportion present in healthy women [14% of 64 consecutive
unrelated healthy women (19)], to detect this 35% difference in the
proportion of women showing skewed X-chromosome inactivation,
with a power of 0.80, the least significant number of subjects in each
group must be 22 [a 5 0.05, one-sided test, normal distribution (21)].
Thus, the number of patients studied here was adequate to evaluate
clinically significant differences in the number of CAG repeats and in the
proportion of subjects showing skewed X-chromosome inactivation,
among patients with idiopathic hirsutism and women with hyperan-
drogenic hirsutism.
The results are expressed as mean (median) 6 sd in the text and tables.
The Kruskall-Wallis nonparametric one-way ANOVA was used to com-
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pare variables among the three groups of subjects. For variables showing
significant differences between the groups by the Kruskall-Wallis test,
repeated Mann-Whitney U–Wilcoxon Rank Sum W tests were used to
identify the differences between each pair of groups, applying an a priori
downward correction to the level of significance to compensate for
multiple comparisons (i.e. P , 0.017 is needed to reach statistically
significant differences, as comparisons involve three groups) (22). A x2
test was used for discontinuous variables. P , 0.05 was considered
statistically significant, with the exception stated above.
Results
Clinical and hormonal characteristics in women with
idiopathic hirsutism and women with hyperandrogenic
hirsutism, as compared with healthy controls
The patients with hyperandrogenic hirsutism were
younger than the controls, whereas the women with idio-
pathic hirsutism had intermediate age that was not different
from any of the other groups (Table 1). There were no dif-
ferences in the BMI among the groups (Table 1), and there
was no difference in the Ferriman-Gallwey score among the
women with idiopathic hirsutism as compared with women
with hyperandrogenic hirsutism [15 (13) 6 5 vs. 17 (15) 6 6,
P 5 0.095].
As expected, serum T, DHEAS, and A levels and the free
androgen index were higher in women with hyperandro-
genic hirsutism as compared with women with idiopathic
hirsutism and to controls (Table 1). Women with hyperan-
drogenic hirsutism also had increased serum 17-OHP lev-
els, as compared with controls, and increased LH and S
levels, as compared with women with idiopathic hirsutism
(Table 1).
Finally, women with idiopathic hirsutism had increased
free androgen index as compared with controls (Table 1), and
SHBG levels were decreased in both groups of hirsute
women as compared with controls (Table 1). There were no
differences among the three groups in F, P4, FSH, and E2
circulating levels (Table 1).
CAG microsatellite analysis
There were no differences in the number of repeats among
the three groups of subjects, whether analyzing all the alleles
together or the smaller and larger alleles separately (Table 1).
Furthermore, there were no correlations between the mean
number of repeats of the pair of alleles of each subject and
the Ferriman-Gallwey score or the hormonal levels (data not
shown).
X-chromosome inactivation analysis
Ten subjects were homozygous for the AR gene, having
the same number of CAG repeats in both alleles, and, there-
TABLE 1. Clinical and hormonal characteristics in women with idiopathic hirsutism and women with hyperandrogenic hirsutism, as
compared with healthy controls
Idiopathic hirsutism (n 5 28) Hyperandrogenic hirsutism (n 5 34) Controls (n 5 15)
Age (yr) 24.8 (22.5) 6 8.2 21.7 (20.5) 6 5.4a 29.5 (28.0) 6 8.1
BMI (kg/m2) 24.6 (24.4) 6 4.6 26.0 (23.6) 6 7.2 23.7 (23.4) 6 4.2
Total T (nmol/L) 1.76 (1.77) 6 0.5 3.01 (2.77) 6 1.0b 1.49 (1.52) 6 0.5
DHEAS (mmol/L) 6.4 (6.1) 6 2.4 10.3 (10.1) 6 4.9b 5.3 (5.0) 6 2.8
Androstenedione (nmol/L) 9.8 (9.7) 6 2.5 14.1 (13.6) 6 6.2b 8.6 (8.4) 6 2.7
Free androgen index 4.85 (4.13) 6 2.80a 11.57 (6.97) 6 14.66b 1.98 (2.17) 6 0.88
SHBG (nmol/L) 41 (33) 6 23a 42 (35) 6 24b 81 (77) 6 26
F (nmol/L) 432 (410) 6 176 476 (490) 6 187 454 (440) 6 140
S (nmol/L) 6.6 (5.8) 6 3.2 10.7 (9.2) 6 6.9c 6.4 (6.4) 6 3.2
17-OHP (nmol/L) 3.1 (2.5) 6 1.9 4.2 (3.8) 6 2.5b 2.5 (2.3) 6 1.2
P4 (nmol/L) 3.0 (3.0) 6 1.2 3.4 (3.5) 6 1.4 2.6 (2.4) 6 0.8
LH (IU/L) 3.8 (3.2) 6 2.3 5.7 (4.6) 6 3.7c 3.9 (3.6) 6 1.6
FSH (IU/L) 4.8 (4.2) 6 2.6 5.2 (4.8) 6 2.5 5.1 (5.3) 6 1.8
E2 (pmol/L) 169 (106) 6 125 154 (128) 6 84 206 (132) 6 165
CAG repeats (shorter allele) 15 (17) 6 3 15 (16) 6 3 15 (16) 6 3
CAG repeats (larger allele) 19 (19) 6 2 19 (19) 6 4 19 (19) 6 4
CAG repeats (both alleles)d 17 (16) 6 4 17 (17) 6 3 17 (17) 6 3
Values are means (median) 6 SD.
a At least P , 0.05 as compared with the control group.
b At least P , 0.05 as compared with the control group and the group of women with idiopathic hirsutism.
c At least P , 0.05 as compared with the group of women with idiopathic hirsutism.
d Both alleles for each individual were analyzed. Homozygous individuals were counted as two alleles.
FIG. 1. Degree of X-chromosome inactivation, as assesed by methyl-
ation analysis using DNA extracted from blood leucocytes, in hirsute
and control women heterozygous for the AR gene. The percentage
represents the amount of total PCR product obtained from methyl-
ated, inactive DNA. Values more than 80% indicate skewed X-chro-
mosome inactivation of the corresponding allele. C, Control group of
healthy women, n 5 13; IH, idiopathic hirsutism, n 5 27; HH, hy-
perandrogenic hirsutism, n 5 27.
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fore, X-chromosome inactivation could not be assessed in
their samples. These subjects were two controls, one patient
with idiopathic hirsutism, and seven patients with hyperan-
drogenic hirsutism.
The remaining 67 subjects had different CAG repeats in
each allele of the AR gene, but there were no differences
among the groups of patients with idiopathic or hyperan-
drogenic hirsutism and controls, in the number of subjects
with skewed X-chromosome inactivation, which was present
in 10 of these 67 women (14.9%): 3 from the group with
idiopathic hirsutism, 5 from the group of hyperandrogenic
hirsutism, and 2 controls (Pearson’s x2 5 0.59, P 5 0.746; Fig.
1 and Table 2).
It should also be noted that in one woman with idiopathic
hirsutism, three patients with hyperandrogenic hirsutism,
and in two control women, it was the shorter allele that was
preferentially inactivated (Fig. 1 and Table 2). Furthermore,
also when considering moderate degrees of skewed X-chro-
mosome inactivation [i.e. between 65–79% (23)], there were
no differences among the groups in the number of subjects
affected (Pearson’s x2 5 7.69, P 5 0.464).
Discussion
Hirsutism is a consequence of increased androgen action
at the pilosebaceous unit. Although most hirsute patients
present increased serum androgens (3), some patients have
normal levels of the main androgens, and their hirsutism is
usually termed “idiopathic.”
The pathophysiologic mechanisms leading to idiopathic
hirsutism are not entirely known. We have previously shown
that most patients with idiopathic hirsutism actually have
mild adrenal and/or ovarian steroidogenic abnormalities (2).
On the contrary, other authors hypothesize that idiopathic
hirsutism may result from abnormalities occurring locally at
the skin. An increased activity of the enzyme 5a-reductase,
which is responsible for the conversion of T into the much
more active dihydrotestosterone, has been proposed as the
cause of idiopathic hirsutism (24–26), but a genetic basis for
this hypothesis has not been demonstrated.
A second possibility is that the AR at the pilosebaceous
unit of women with idiopathic hirsutism are more sensitive
to their normal levels of circulating androgens than those
from nonhirsute women.
As the binding of androgens to the AR is not increased in
hirsute patients (25), other explanations are needed to justify
this increased sensitivity of their AR. The AR is a protein that
contains a polyglutamine chain in its N-terminal domain, in
which the transactivation activity of the AR resides (6). The
polyglutamine chain is encoded by a variable number of
CAG repeats located in exon 1 of the AR gene. The expansion
of the CAG repeats length decreases the transactivation of the
AR in vitro (6), and, as stated above, inverse relationships
have been described between the number of CAG triplets in
the AR gene with the risk for prostate cancer and its severity
(7, 8).
Recently, an inverse correlation between the number of
CAG triplets in the AR gene and the hirsutism scores has
been reported (9). Moreover, shorter AR gene alleles has been
described in association with androgenic disorders of the
skin in men and women, including acne, androgenetic alo-
pecia, and hirsutism, as compared with healthy controls (10).
Taken together, these observations suggest that shorter AR
alleles result in more active AR protein (11).
Our present results, on the contrary, do not support a role
for shorter AR alleles, containing less CAG repetitions, in
both idiopathic or hyperandrogenic hirsutism. On the one
hand, the mean number of CAG repeats were not different
in women diagnosed with idiopathic hirsutism as compared
with patients with hyperandrogenic hirsutism and as com-
pared with healthy women. Moreover, short alleles, contain-
ing 10 or less CAG repeats, were found in all these groups
of women, in contrast to a recent report, in which these
shorter alleles were found only in women with idiopathic
hirsutism (11). Finally, we have not found any correlation
between the number of CAG repeats and the Ferriman-Gall-
wey score, or any of the hormone levels of the subjects
studied here.
A provocative novel hypothesis has been proposed re-
cently by Vottero et al. (11). All human female cells undergo
inactivation of one of their X-chromosomes. Because the AR
gene is located in the X-chromosome, and shorter alleles may
be associated with increased AR activity, skewed inactiva-
tion of larger AR alleles in the skin would result in increased
AR activity (11).
Skewing of X-chromosome inactivation seems to be an
inherited character linked to specific loci of the X-chromo-
some (27, 28). In most human studies, the phenotype has
been transformed into a qualitative character by defining a
threshold value. X-chromosome inactivation is considered to
be skewed when 80% or more of the cells of one individual
show the same X-chromosome active (19, 23).
X-chromosome inactivation correlates with methylation of
HpaII and HhaI sites near the polymorphic CAG repeats in
exon 1 of the AR gene (12), because methylation is an im-
TABLE 2. X-chromosome inactivation, in women with idiopathic hirsutism as compared with women with hyperandrogenic hirsutism and
with healthy controls
Idiopathic hirsutism (n 5 27) Hyperandrogenic hirsutism (n 5 27) Controls (n 5 13)
Shorter allele Larger allele Shorter allele Larger allele Shorter allele Larger allele
Subjects with skewed X-chromosome inactivation 1 2 3 2 2 0
Degree of X-chromosome inactivation (%)a 48 (42) 6 20 53 (59) 6 21 47 (47) 6 20 53 (53) 6 20 59 (58) 6 19 41 (42) 6 19
Values are means (median) 6 SD. Only women found to be heterozygous for the AR gene were analyzed. No statistically significant differences
were found among the groups in any of the variables.
a HpaII digests only unmethylated, active, DNA. Therefore, the percentage for each allele of PCR product using digested DNA is inversely
proportional to the number of cells having it as the active allele (i.e. an individual with 80% of the PCR product coming from the larger allele
means that 80% of the cells had the larger allele methylated, and, therefore, inactive, and conversely, 80% cells have the shorter allele as the
active allele).
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portant mechanism in silencing gene expression during X-
chromosome inactivation. X-chromosome inactivation is
usually assessed using DNA extracted from blood mononu-
clear cells. Thus, the possibility exists that the X-chromosome
inactivation pattern in the hair follicle may be different from
that found in tissues. However, skewed X-chromosome in-
activation, as assayed from lymphocyte DNA, has been
shown to influence the clinical expression of X-linked reces-
sive traits, such as dystrophinopathy (18) and myotubular
myopathy (23). Therefore, the pattern of X-chromosome in-
activation in blood mononuclear cells might be a useful
marker of X-chromosome inactivation in tissues.
We have found skewed X-chromosome inactivation in 10
(14.9%) of 67 women heterozygous for the AR gene, a pro-
portion similar to the 14% prevalence of skewed X-chromo-
some inactivation found in a series of 64 unrelated control
women (19). In addition, these women were not differently
distributed among women with idiopathic hirsutism,
women with hyperandrogenic hirsutism, and healthy
controls.
In our series, only 3 of the 28 women with idiopathic
hirsutism had skewed X-chromosome inactivation, and in
one of these 3 patients the smaller AR allele, and not the
larger allele, was preferentially inactivated, a mechanism
that may lead to decreased AR activity. Furthermore, skewed
X-chromosome inactivation was also found in a similar pro-
portion of women with hyperandrogenic hirsutism and in
controls, inactivating the larger or the shorter allele depend-
ing on the subject. Therefore, skewed X-chromosome inac-
tivation plays a minor role, if any, in the pathogenesis of
hirsutism in our series, including the subgroup of hirsute
patients presenting with normal levels of circulating
androgens.
On the contrary, Vottero et al. (11) found skewed X-chro-
mosome inactivation in most of the 16 women with nonhy-
perandrogenic hirsutism included in their study. The meth-
ods used in both studies are essentially the same (comparison
of the PCR products obtained with or without prior digestion
with a methylation-sensitive endonuclease), although Vot-
tero et al. (11) have used autoradiographic measurement of
the optical densities of the radioactivity-marked primers to
evaluate the PCR product and we have used an automated
DNA sequencer to detect the primers labeled with a fluo-
rescent dye.
The method used to evaluate skewed X-chromosome in-
activation in the present study has several advantages over
the method used by Vottero et al. (11), as pointed out by other
authors (12, 18). On the one hand, the simplicity of the
method has allowed us to evaluate a much larger series of
hirsute patients, with or without hyperandrogenism, and
healthy controls, giving the study the statistical power to
correctly conclude the absence of an association between
skewed X-chromosome inactivation and hirsutism.
Moreover, according to Pegoraro et al. (18), for each subject
we have introduced a correction factor to compensate for
unequal amplification of alleles. Also, the 80% cut-off value
used in our study to define skewed X-chromosome inacti-
vation, which might be more strict than the 0.4 decrease in
optical density used by Vottero et al. (11), is widely supported
by previous studies from other groups (19, 23) and is based
on the original description of nonrandom X-chromosome
inactivation in extraembryonic tissues of the mouse (29).
These factors, and also the different ethnicity of the popu-
lations studied, might have influenced the differences be-
tween our present results and those of Vottero et al. (11).
In conclusion, our present results in unselected women
with idiopathic or hyperandrogenic hirsutism do not sup-
port a role for AR-mediated hypersensitivity to androgens in
the pathogenesis of hirsutism, at least by a mechanism in-
volving the CAG repeat in the AR gene, or skewed X-chro-
mosome inactivation.
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